GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » YoY EPS Growth

Acasti Pharma (TSXV:ACST) YoY EPS Growth : 0.00% (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Acasti Pharma's YoY EPS Growth for the quarter that ended in Dec. 2024 was 0.00%.

Acasti Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was C$0.00.

Acasti Pharma YoY EPS Growth Historical Data

The historical data trend for Acasti Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma YoY EPS Growth Chart

Acasti Pharma Annual Data
Trend Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.10 50.09 79.55 100.00 -

Acasti Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 - - - -

Acasti Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Acasti Pharma's YoY EPS Growth for the fiscal year that ended in Mar. 2024 is calculated as:

YoY EPS Growth (A: Mar. 2024 )
=(Earnings per Share (Diluted) (A: Mar. 2024 )-Earnings per Share (Diluted) (A: Mar. 2023 ))/ | Earnings per Share (Diluted) (A: Mar. 2023 ) |
=(0-0)/ | 0 |
=N/A %

Acasti Pharma's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EPS Growth (Q: Dec. 2024 )
=(Earnings per Share (Diluted) (Q: Dec. 2024 )-Earnings per Share (Diluted) (Q: Dec. 2023 )) / | Earnings per Share (Diluted) (Q: Dec. 2023 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acasti Pharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » YoY EPS Growth
Comparable Companies
KZR LVTX OSTX PPCB OKUR ALGS NRXP DYAI BOLD CVKD VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
GRCE:USA
Address
103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Website
https://www.acastipharma.com
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Executives
Donald John Olds Director
Jean-françois Boily Senior Officer
Jean-marie Canan Director

Acasti Pharma Headlines

No Headlines